Healthcare Market Dynamics
Expert articles and analysis related to healthcare market dynamics.
AI Summary — Last 7 Days
CMS is pushing mandatory episode-based accountability deeper into post-acute and surgical care, with expanded joint replacement model participation slated by 2028—raising stakes for hospitals, SNFs, home health agencies, and conveners to manage discharge networks, readmissions, and total cost performance under bundled-payment economics (Home Health Care News). At the same time, Medicare Advantage and ACA Marketplace dynamics are becoming more uneven: Clover is raising its outlook on MA growth, UnitedHealthcare is cutting MA plans in 34 counties, and insurer exits from ACA markets are creating local volatility that will affect risk pools, network strategy, and provider contracting leverage. For VBC stakeholders, the week’s throughline is sharper market selection—plans are pruning geographies and products while CMS expands mandatory payment models, forcing providers and ACOs to prepare for more downside exposure amid unstable payer participation and rising medical cost pressure (Wakely).
Related Articles
SUSTAIN 340B Act proposes major changes for hospitals and pharmacies
A bipartisan working group in Congress released a preliminary legislative draft that attempts to resolve some of the most disputed aspects of the 340B Drug Pricing Program. One noteworthy provision in...
340B Purchases Surge Past $100 Billion
State Pricing Controls at an Inflection Point: MFP and the Shifting PDAB Landscape
Michigan revives Eli Lilly insulin pricing probe
Michigan revives Eli Lilly insulin pricing probe Becker's Hospital Review
STAT+: The latest orphan drug exemptions may not be warranted, analysis finds
A new analysis questions the wisdom of a controversial provision in federal law that exempts so-called orphan drugs from Medicare pricing negotiations.
Pharmaceutical Spending Is Shifting Away From ‘Me-Too’ Drugs
Drug spending has become increasingly concentrated on innovative medicines, largely due to greater patient use rather than higher prices. The post Pharmaceutical Spending Is Shifting Away From ‘Me-Too...
STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing
Lilly was accused of charging “grossly” excessive prices for different insulin products that forced some patients to ration or forgo the drug.
A digital health company became an insurance carrier under the thin veil of a product launch
By DEEKSHA HEGDE How to spot a fundamental business model shift from a mile away, long before the PR calls it a product launch or market expansion. In April 2026, Progyny, aContinue reading...
Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19
Highly Novel Drugs Outperformed Less Novel Drugs In Gross And Net Revenues In The US, Driven Primarily By Utilization, 2013–19 Health Affairs
Prescription spending shifts to innovative drugs: 5 notes
Prescription spending shifts to innovative drugs: 5 notes Becker's Hospital Review